Heat shock proteins (HSPs) are recognized as significant participants in immune reactions. We previously reported that expression of HSP70 in response to hyperthermia, produced using our original magnetite cationic liposomes (MCLs), induces antitumor immunity. In the present study, we examine whether the antitumor immunity induced by hyperthermia is enhanced by hsp70 gene transfer. A human hsp70 gene mediated by cationic liposomes was injected into a B16 melanoma nodule in C57BL/6 mice in situ. At 24 hours after the injection of the hsp70 gene, MCLs were injected into melanoma nodules in C57BL/6 mice, which were subjected to an alternating magnetic field for 30 minutes. The temperature at the tumor reached 431C and was maintained by controlling the magnetic field intensity. The combined treatment strongly arrested tumor growth over a 30-day period, and complete regression of tumors was observed in 30% (3/10) of mice. Systemic antitumor immunity was induced in the cured mice. This study demonstrates that this novel therapeutic strategy combining the use of hsp70 gene therapy and hyperthermia using MCLs may be applicable to patients with advanced malignancies.
H yperthermia is a promising approach for cancer therapy. 1, 2 However, the inevitable technical problem with hyperthermia is the difficulty in heating only the local tumor region to the intended temperature without damaging the surrounding normal tissue. Magnetic nanoparticles have been used for hyperthermia treatment in an attempt to overcome these disadvantages. 3, 4 Magnetic nanoparticles generate heat in an alternating magnetic field (AMF) due to hysteresis loss. 5 We have developed magnetite cationic liposomes (MCLs) for intracellular hyperthermia. 6, 7 The hyperthermic effect of MCLs was examined in an in vivo study, and complete tumor regression was observed. 8 Since some researchers have reported that heat treatment itself can enhance the immunogenicity of cancer cells, [9] [10] [11] [12] we previously investigated hyperthermia-induced antitumor immunity in T-9 rat glioma cells in vivo. 13 This induced immunity continued for an extended period of time, and the rats treated with hyperthermia completely rejected T-9 cells as a metastasis model. Moreover, we investigated the mechanisms of antitumor immunity induced by intracellular hyperthermia with regard to the role of heat shock proteins (HSPs). 14, 15 HSPs are a highly conserved group of intracellular proteins whose synthesis is increased by a large variety of stressors including heat shock. 16 As expression of HSP70 protects cells from heat-induced apoptosis, 17 HSP70 expression is considered a complicating factor in hyperthermia. On the other hand, recent reports have shown the importance of HSPs, such as HSP70, HSP90, and glucose-regulated protein 96 (gp96), in immune reactions. 18, 19 A possible mechanism by which HSPs influence tumor cell immunogenicity is associated with the processing and presentation of endogenous tumor antigens directly to tumor-specific T cells. 20 Srivastava and coworkers [21] [22] [23] proposed the following relay line model for tumor antigenic peptide transfer during antigen processing and presentation by HSPs. First, peptides are bound to HSP70 (or HSP90), which is responsible for carrying them to the endoplasmic reticulum (ER) through the transporter associated with antigen processing (TAP). The peptides are then transferred to gp96 in the ER lumen. In the terminal step, gp96 transfers the peptides to the MHC class I-b 2 microglobulin complexes. Me´noret et al 24 proposed that this entire pathway could be ''upgraded'' under pathologic conditions of oxidative stress. We applied these ideas to hyperthermia and demonstrated heat-induced expression of MHC class I antigen on cells via HSP70 as a possible mechanism for hyperthermia-induced antitumor immunity.
We previously demonstrated that HSP70 expression following hyperthermia induced antitumor immunity against the T-9 rat glioma. 15 Our hyperthermia system using MCLs induced necrotic cell death in which HSP70 expression occurred. We purified the HSP70-peptide complexes from the tumor after hyperthermia, and found that rats immunized with the T-9-derived HSP70 significantly suppressed tumor growth. A tumor rejection assay was performed after hyperthermia treatment of implanted T-9 cells using incorporated MCLs. Tumor growth was strongly suppressed in rats in which implanted T-9 cells were subjected to hyperthermia, and 50% of rats were protected from challenge with T-9 cells. The immunogenicity was enhanced when the HSP70-overexpressing T-9 cells, which constitutively expressed HSP70 upon ex vivo gene transfer, were killed via necrosis by hyperthermia. After this treatment, all rats were completely protected from challenge with T-9 cells. These results suggest that our hyperthermia system produces an HSP70-peptide vaccine via necrotic tumor cell death in vivo, resulting in antitumor immunity. This phenomenon, called in situ vaccination, has important implications for the development of novel antitumor therapies.
When applying hyperthermia as a tumor vaccine, administration of immunostimulant may supplement the vaccine-induced response against tumor cells. In the present study, we chose HSP70 as a natural immunostimulant. We studied the combined effects of hsp70 gene transfer into tumors in situ and hyperthermia using MCLs on melanoma, and investigated the feasibility of this novel strategy in vivo. To the best of our knowledge, this is the first time that the combination of hsp70 gene therapy and hyperthermia has been shown to exhibit an obvious antitumor effect against malignant melanoma.
Materials and methods

Cell line and establishment of tumors in mice
Mouse B16 melanoma cells (Riken Cell Bank, Tsukuba, Japan) were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin G and 0.1 mg/ml streptomycin). Cells were grown at 371C in an atmosphere containing 5% CO 2 . Female C57BL/6 mice (age, 4 weeks) were purchased from Charles River Japan (Yokohama, Japan). To prepare tumor-bearing animals, cell suspensions including approximately 1 Â 10 6 melanoma cells in 0.1 ml phosphate buffer saline (PBS) were injected subcutaneously into C57BL/6 mice, which were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight). Melanoma nodules growing to 6 mm in diameter were used for the experiments. The tumor diameter was measured every 3 days and the size was determined by the following formula:
Tumor volume ¼ 0:5ðlength Â width 2 Þ where length and width are measured in millimeters.
Animal experiments were performed according to the principles laid down in the ''Guide for the Care and Use of Laboratory Animals'' prepared under the directions of the Office of the Prime Minister of Japan.
Plasmid construction and in situ gene transfer
The pCMVhsp plasmid was kindly provided by Dr Kenzo Ohtsuka (Aichi Cancer Center, Japan). This plasmid containing the human-inducible hsp70 cDNA and the hygromycin resistance gene has been described previously. 14, 15 The hsp70 cDNA was located under the CMV promoter. The pCMVnull plasmid was constructed by blunt-end ligation at XbaI and KpnI sites, resulting in the exclusion of the hsp70 cDNA from the pCMVhsp plasmid. A total of 20 mg of these plasmids was injected into the tumors by the lipofection method, which used N-(atrimethylammonioacetyl)-didodecyl-d-glutamate chloride (Sogo Pharmaceutical, Tokyo, Japan), dilauroylphosphatidylcholine (Sigma Chemical, St Louis, MO), and dioleoylphosphatidyl-ethanolamine (Sigma Chemical) in a 1:2:2 molar ratio as described previously. 29 The DNAliposome transfection vehicle was directly injected into tumors in situ.
Preparation of MCLs and hyperthermia treatment
Magnetite (Fe 3 O 4 ; average particle size: 10 nm), used as the MCL core, was a kind gift of Toda Kogyo (Hiroshima, Japan). The MCLs were prepared with colloidal magnetite and a lipid mixture consisting of N-(a-trimethylammonioacetyl)-didodecyl-d-glutamate chloride, dilauroylphosphatidyl-choline, and dioleoylphosphatidyl-ethanolamine in a 1:2:2 molar ratio as previously described. 6 All MCL concentrations are expressed as the net magnetite concentration.
At 1 day after gene transfer, 0.1 ml of MCL solution (net magnetite weight: 2 mg) was injected at the center of the tumor using a 26-gauge needle and an infusion pump (SP100i; World Precision Instruments, Sarasota, FL) for 30 minutes. Mice were subsequently subjected to hyperthermia treatment. A magnetic field was created using a horizontal coil (inner diameter: 7 cm; length: 7 cm) with a transistor inverter (LTG-100-05; Dai-ichi High Frequency Co., Tokyo, Japan). 8 Anesthetized mice were laid inside the coil such that the tumor region was at the center. The magnetic field frequency and intensity were 118 kHz and 30.6 kA/m (384 Oe), respectively. Tumor and rectal temperatures were measured using an optical fiber probe (FX-9020; Anritsu Meter, Tokyo, Japan).
ELISA for HSP70 protein expression
On the day following hyperthermic treatment, tumors were removed and homogenized using the Medimachine System (DAKO A/S., Glostrup, Denmark). Inducible HSP70 protein in the tumor extract was assayed by an Hsp70 EIA Kit (StressGen Biotechnologies, British Columbia, Canada), which can detect and quantitate inducible HSP70 in samples originating from both human and mouse. ELISA was performed according to the HSP70 gene therapy with hyperthermia A Ito et al manufacturer's instructions. The total protein content of the tumor homogenates was determined using the DC protein assay reagent (Bio-Rad Laboratories, Hercules, CA).
In vitro cytotoxicity assay
Splenic lymphocytes, derived from cured mice that were treated with hsp70 gene plus hyperthermia, were isolated at 14 days after the hyperthermic treatment using the Medimachine System (DAKO). Naive mice that were born at nearly the same time were used as controls. Splenic lymphocytes depleted erythrocytes in the presence of 0.75% ammonium chloride. Cytotoxic activity was determined by lactate dehydrogenase (LDH) release assay 30 according to the manufacturer's instructions (Promega, Madison, WI). In brief, target cells (B16 cells, 5 Â 10 4 cells) were mixed with different ratios of effector cells and incubated for 4 hours at 371C in an atmosphere containing 5% CO 2 . The release of LDH was then evaluated. The percent cytotoxicity was calculated as follows:
À OD target spontaneous Þ=ðOD target maximum À OD target spontaneous ÞÞ Â 100
Statistical analysis
Levels of statistical significance in the HSP70 expression and tumor growth experiments were evaluated using the Mann-Whitney rank sum test. For survival analysis, differences in survival rates were analyzed by a log-rank test.
Results
MCL-induced hyperthermia
At 1 day after gene transfer, MCLs were injected into the tumor and AMF was applied over the whole body of the mouse. Figure 1 shows the temperature at the tumor surface and in the rectum during irradiation with the AMF. Tumor temperature increased rapidly to 431C within 3 minutes and was then maintained for 30 minutes by controlling the intensity of the AMF. When the AMF was turned off, tumor temperature decreased to 36.51C within 5 minutes. In contrast, the temperature in the rectum increased only slightly during the irradiation. This suggests that the MCLs injected into the tumor were specifically heated by the AMF and that heat generation was controllable by adjusting the power of the AMF generator.
Inducible HSP70 concentration after hyperthermia treatment in the tumors
The pCMVhsp-containing cationic liposomes were injected into tumors, hyperthermia was induced using MCLs, and the concentration of human and mouse inducible HSP70 was measured in tumor homogenates at 24 hours after hyperthermia (Figure 2 ). For nontreated (Nontreated group) and pCMVnull vector-transfected-control Figure 2 Inducible HSP70 concentration after hyperthermia treatment in the tumors. Human and mouse inducible HSP70 concentration in the tumors was determined by ELISA. Tumors were derived from nontreated mice (nontreated group), pCMVnull-transfected mice (pCMVnull group), hyperthermia-treated mice (hyperthermia group), pCMVnull-transfected plus hyperthermia-treated mice (pCMVnull+hyperthermia group), and pCMVhsp-transfected plus hyperthermia-treated mice (pCMVhsp+hyperthermia group). Data points and bars are the means and SDs from five mice.
HSP70 gene therapy with hyperthermia
A Ito et al (pCMVnull group) mice, expression levels of inducible HSP70 were very low. When the human-inducible hsp70 gene was transferred into the tumor (pCMVhsp group), HSP70 expression was observed in the tumor. As native mouse HSP70 was induced by hyperthermia, inducible HSP70 expression was also observed in the tumors of hyperthermia-treated mice (hyperthermia group and pCMVnull+hyperthermia group). The highest concentration of inducible HSP70 was detected in the combined therapy group (pCMVhsp+hyperthermia group). The increase in inducible HSP70 expression in the combined therapy group could thus be attributed to the human hsp70 gene transferred into the tumor in situ and native mouse HSP70 expression following hyperthermia.
Therapeutic effect of hsp70 gene therapy combined with MCL-induced hyperthermia Figure 3 shows the time courses of tumor growth in 10 mice in each group. In a control group of mice, MCLs were injected but AMF was not applied. Tumor volume increased over 30 days in the control group as shown in Figure 3a . In both the hyperthermia group (Fig 3b) , which received MCLs and AMF treatment, and the hsp70 gene therapy group (Fig 3c) , which received injections of both pCMVhsp-containing liposomes and MCLs but not AMF irradiation, tumor volume at 30 days after treatment was not significantly suppressed when compared with the control group (P ¼ 1.0 and 0.72, respectively). In the control gene transfer plus hyperthermia group (Fig 3d) , which received injections of both pCMVnull-containing liposomes and MCLs and at AMF irradiation, tumor volume was also similar to that observed for the control group (P ¼ .11). In the combined therapy group (Fig 3e) The survival percentage of tumor-bearing mice over a period of 90 days after hyperthermia is shown in Figure 4 . Since B16 is known to be a highly metastatic cancer and mice tend to die from pulmonary metastases after tumor inoculation, the lung was extirpated from all mice that died, and was examined for pulmonary metastases. In the control groups, including the hyperthermia, the hsp70 gene therapy, and pCMVnull gene transfer plus hyperthermia group, all mice died within 48 days from pulmonary metastases despite bearing small tumors and/ or an enlarged tumor at the inoculated site. Three of 10 mice in the combined therapy group were completely cured and remained alive at 90 days after hyperthermia. Even though all mice examined could not be cured completely by the combined therapy, survival was significantly prolonged when compared with the other groups (Po.05, versus that of all the other groups). 
HSP70 gene therapy with hyperthermia A Ito et al
Antitumor immunity induction by a combination of hsp70 gene therapy with hyperthermia using MCLs
We performed an in vitro cytotoxicity assay to examine whether combined therapy induced antitumor immunity against melanoma cells. Splenic lymphocytes were derived from cured mice (in the combined therapy group) and naive mice. As shown in Figure 5 , splenic lymphocytes from the cured mice showed cytotoxic activity against B16 melanoma cells and this activity was substantially higher than that of spleen cells from the naive mice.
Discussion
Hyperthermia has been used for many years to treat a wide variety of tumors in experimental animals and patients. The most commonly used heating method in clinical settings is capacitive heating using a radiofrequency (RF) electric field. 31 However, specifically heating tumors by capacitive heating using an RF electric field is difficult, because heating characteristics are influenced by various factors including thickness of adipose layer, depth of tumor, tumor size, position of electrodes, and uneven adhesion of electrodes at certain sites. Although hyperthermia induces necrotic cell death (in principle, in any type of tumor cell), the heating process is generally quite mild because of potential adverse effects on nontarget organs or tissues. On the other hand, our intracellular hyperthermia treatment is able to heat the tumor specifically by means of the MCLs, as shown in Figure 1 . Moreover, the degree of heat generated in the tumor can be controlled via the magnetic field intensity, which makes it possible to induce necrotic cell death without damaging the surrounding normal tissues. In the present study, we set the tumor temperature at 431C, but this was insufficient to destroy the malignant melanoma. Our hyperthermia system can achieve higher temperatures and can be applied repeatedly without damaging healthy tissue. For example, complete regression of B16 melanoma was previously observed in 90% of mice using our hyperthermia system once daily for 2 days at 461C. 32 In the present study, the treatment temperature was set to 431C in order to examine the effects combining hyperthermia with hsp70 gene therapy.
Several reports have suggested that ex vivo hsp70 gene transfer into tumor cells increases antitumor immunity. We previously reported that transfection of human hsp70 gene into rat T-9 glioma cells enhanced the immunogenicity of the T-9 cells.
14, 15 Wells et al 33 have reported that transfection of human hsp70 gene into mouse B16 melanoma cells restored deficient presentation of lymphocytic choriomeningitis virus (LCMV) antigen by MHC class I molecules to specific CD8-positive cytotoxic T lymphocytes. Todryk et al 34 have reported that stable transfection of mouse hsp70 gene into colorectal tumor and melanoma enhanced tumor immunogenicity, promoted infiltration of T cells and antigen presenting cells (APCs), and increased secretion of Th1-type cytokines. In addition to these ex vivo studies, the effects of in situ gene transfer of hsp70 into tumors have also been reported. 35 Transfer of the rat hsp70 gene in situ eradicated small (0.2 cm in diameter) EL-4 tumors in mice and induced acquisition of systemic antitumor immunity. In the present study, a human hsp70 gene was injected into tumors in mice. Here, a xenogeneic human form of hsp70 was employed because the function of human hsp70 in mice was previously examined and no adverse effects were reported, suggesting that human hsp70 is not toxic in mice. Figure 3c shows that the human hsp70 gene transfer into melanoma nodules in situ alone did not decrease the tumor volume. We previously showed that B16 mouse melanoma cells were poorly immunogenic and express a lower amount of H-2 antigen as compared with that of EL-4 cells. 36 In addition to the low immunogenicity, we used larger established tumors (0.6 cm in diameter) to examine the preclinical feasibility of the combined therapy used in the present study.
The most important finding of our studies was that hsp70 gene transfer proved to be a powerful immunostimulant for hyperthermia. HSP70 expression in cells is known to induce thermotolerance, [37] [38] [39] which would negatively affect hyperthermia treatment. By pretreating the tumors with the hsp70 gene, a larger amount of HSP70 was detected after hyperthermia as shown in Figure 2 . The increase in inducible HSP70 expression in the mice treated with the combined therapy could be attributed to human hsp70 gene transfer into the tumor in situ and native mouse HSP70 expression following hyperthermia. Interestingly, HSP70 concentration in the tumors treated with combined therapy (pCMVhsp+hy-perthermia group, 137 ng/mg-protein) was much higher than the sum of the HSP70 concentrations observed in the pCMVhsp (12 ng/mg-protein) and hyperthermia groups (52 ng/mg-protein). Since transfection with the control vector (pCMVnull) did not enhance HSP70 expression after hyperthermia (pCMVnull+hyperthermia group), we believe that pretreating with hsp70 gene transfer facilitated native hyperthermia-induced HSP70 expression. HSP70 plays a role in protection against heatinduced cell death due to its chaperone activity, 17 and thus constitutive expression of human-inducible HSP70 by gene transfer into the tumor may lead to thermotolerance against subsequent hyperthermia treatment. We speculate that the tumors transfected with hsp70 gene resisted subsequent hyperthermia treatment and expressed higher levels of HSP70, while tumors treated with only hyperthermia expressed lower levels of HSP70 as a result of heat-induced cell death following treatment. Udono and Srivastava 40 reported that the HSP70 vaccination effect was directly dependent on the dose of HSP70. Figure 3 shows that tumor growth was arrested in mice receiving the combined therapy (hsp70 gene and hyperthermia). Me´noret et al 24 suggested that interaction of inducible HSP70 with polypeptide substrates may preferentially occur in an oxidized milieu, because stresses that induce HSP70 expression also give rise to cellular oxidation. As hyperthermia is known to induce intracellular oxidation and HSP synthesis, 41 hyperthermia may promote an adaptive immune response specific for newly chaperoned peptides. These new peptides produced in response to hyperthermia may be more rapidly chaperoned by the overexpressed HSP70. The roles of hsp70 gene therapy in combination with hyperthermia and the relationship between thermotolerance and immune induction remain to be fully elucidated.
We showed that the combination of hsp70 gene therapy and hyperthermia generated systemic antitumor immunity. Cured mice were found only in the combined therapy group, and antitumor immunity was induced in these animals (Fig 5) . Although seven mice died from pulmonary metastases and/or an enlarged tumor induced by the subcutaneous injection of B16 cells, survival was prolonged in the combined therapy group, as shown in Figure 4 . These results indicate that this combined therapy kills tumor cells not only through the direct effects of heat but also via the immune response.
B16 mouse melanoma cells are known to be poorly immunogenic because they express smaller amounts of H-2 antigen, and are thus widely utilized in immunological experiments to assess the effects of immunotherapy. 32, 33, 36 Flow cytometric analysis using anti-mouse H-2K b antibody revealed that B16 cells expressed little or no MHC class I antigen compared with EL4 cells. Efficient recognition of tumor cells by cytolytic T lymphocytes (CTL) is often dependent on the presentation of cytosolic peptides in the context of MHC class I molecules. This process may be influenced by HSP70 expression. Wells et al 33 reported that stably transfected clones of B16 that constitutively express human HSP70 exhibited significantly increased levels of MHC class I antigens on their surface. This HSP70-mediated upregulation of surface MHC class I antigens represented an increase in the amount of functional MHC-peptide complexes as measured by conformation-dependent antibodies and recognition by MHC class I-restricted CTL. In addition, we previously demonstrated the augmentation of MHC class I antigen presentation via endogenous HSP70 expression after hyperthermia. 14 The T-9 rat glioma cell surface presentation of MHC class I antigen increased in tandem with increased HSP70 expression, and the immunogenicity of the cells was enhanced by hyperthermia.
We previously demonstrated the augmentation of H-2K b presentation in B16 melanoma cells by hyperthermia, 36 and that hyperthermia induced antitumor immunity specific to B16 cells. 32 In the present study, although we have not elucidated the effector cells involved in combined hsp70 gene therapy and hyperthermia, we believe that the antitumor immunity specific to B16 melanoma induced by hsp70 gene transfer was enhanced by the subsequent hyperthermia. As H-2K b expression on nonheated B16 cells is low, the role of other effector cells, such as natural killer cells, remains to be investigated.
In human clinical applications, the antigenicity of HSP70 itself by gene transfer can present a substantial problem. HSP70 is normally located in the cytoplasm of cells, suggesting that the immune system is rarely confronted with HSP70 expressed via gene transfer. On the other hand, when HSP70 in the tumor cells is released after cell death by hyperthermia or tumor-specific T cells, HSP70 itself may be recognized by immune system. This release of HSP70 could reflect a danger signal, 42 attracting numerous members of the immune system to initiate a broad primary immune response. However, Breloer et al 43 reported that an HSP70 preparation derived from tumor tissue lost its immunogenicity when the low-molecular weight peptides were dissociated. Furthermore, these peptides (representing defined, MHC-restricted T-cell epitopes isolated from HSP preparations) were able to stimulate specific T-cell clones. These results suggest that HSP70 is not itself the antigen. On the other hand, HSP70 itself functions as an extracellular protein with regulatory effects on human monocytes, having a role as a cytokine. 44 HSP70 elicits a potent proinflammatory cytokine response, and the presence of peptide in the HSP70 preparation is not required for spontaneous activation of the innate immune system. 45 We previously showed that exogenous recombinant HSP70 enhanced antitumor immunity induced by hyperthermia, which suggests that HSP70 itself is an immunositumulant effect. 46 Therefore, because HSP70 gene therapy combined with hyperthermia may induce both innate and adaptive immunity, the precise mechanism should be elucidated before clinical application of this therapy in humans.
We conclude that this novel approach, using a combination of hsp70 gene therapy and hyperthermia induced using MCLs, may be applicable to patients with advanced malignancies.
